Every material Form 8-K Innospec filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Innospec reported third-quarter 2025 revenue of $441.9 million, nearly flat with $443.4 million a year earlier, while net income fell to $12.9 million from $33.4 million. GAAP results include $24.4 million of net charges tied to impairments and restructuring, and the Board declared a semi-annual dividend of 87 cents per share, a 10 percent increase.
Q3 2025 net sales were $441.9 million versus $443.4 million in Q3 2024; diluted EPS was 52 cents versus $1.33
Adjusted non-GAAP EPS was $1.12 versus $1.35 a year earlier; net charges of $24.4 million cut GAAP EPS by 57 cents
Board declared a semi-annual dividend of $0.87 per share, payable November 26, 2025, to holders of record on November 18, 2025
Net cash was $270.8 million at September 30, 2025, with no debt, and $10.7 million of share repurchases were made in the quarter
Innospec reported results for the quarter ended June 30, 2025, in a press release furnished under Item 2.02. Revenue rose 1% but net income fell to $23.5 million, or 94 cents per diluted share, from $31.2 million, or $1.24, a year earlier, with the company citing lower results in Performance Chemicals and Oilfield Services.
Total revenue was $439.7 million, up 1% from $435.0 million a year earlier.
Net income was $23.5 million, or 94 cents per diluted share, versus $31.2 million, or $1.24, in the prior-year quarter.
Adjusted non-GAAP EPS was $1.26 versus $1.39 a year earlier; Performance Chemicals operating income fell 33% to $14.3 million.
The company reported net cash of $266.6 million with no debt and $8.2 million in share repurchases during the quarter.
Innospec reported first-quarter 2025 revenue of $440.8 million, down 12% from $500.2 million a year earlier, and diluted GAAP EPS of $1.31 versus $1.65. Management said tariff uncertainty will delay its recovery targets in Performance Chemicals and Oilfield Services, while the board raised the semi-annual dividend 10% to $0.84 per share.
Revenue $440.8 million vs $500.2 million; net income $32.8 million vs $41.4 million
Adjusted non-GAAP EPS $1.42 vs $1.75; Oilfield Services revenue fell 37% to $102.1 million
Semi-annual dividend of $0.84 per share, payable May 30, 2025 to holders of record May 20, 2025
Cash and cash equivalents of $299.8 million at March 31, 2025 with no debt
Innospec reported fourth-quarter 2024 net sales of $466.8 million, down 6% from a year earlier, and a net loss of $70.4 million, or $2.80 per diluted share, driven by a non-cash $155.6 million charge on the buy-out of its UK pension scheme. Excluding special items, adjusted EPS fell to $1.41 from $1.84, and full-year 2024 revenue fell 5% to $1.85 billion, so the charge and weaker sales weigh on shareholder results even as Performance Chemicals and Fuel Specialties operating income grew.
Q4 2024 net sales were $466.8 million, down 6% from $494.7 million in Q4 2023
Q4 GAAP net loss of $70.4 million, or $2.80 per diluted share, including a $155.6 million non-cash UK pension settlement charge
Adjusted EPS was $1.41 in Q4 versus $1.84 a year earlier; full-year adjusted EPS was $5.92 versus $6.09
Net cash was $289.2 million at December 31, 2024, compared with $203.7 million a year earlier
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Innospec filing is on SEC EDGAR ↗. 8-K briefs of other companies →